DYN
Price
$16.03Alerts
Change
+$0.16 (+1.01%)
Updated
Nov 19 closing price
Capitalization
3.37B
105 days until earnings call
Intraday BUY SELL Signals
XFOR
Price
$2.96Alerts
Change
-$0.02 (-0.67%)
Updated
Nov 19 closing price
Capitalization
315.29M
124 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DYN vs XFOR

DYN vs XFOR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DYN vs. XFOR commentary
Nov 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and XFOR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DYN with price predictions
Nov 18, 2026

DYN sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for DYN moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for DYN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 32 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DYN as a result. In 67 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for DYN turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

DYN moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for DYN crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +7.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where DYN advanced for three days, in 237 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 224 of 248 cases where DYN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.806) is normal, around the industry mean (3.592). P/E Ratio (-5.543) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. DYN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for XFOR with price predictions
Nov 19, 2026

XFOR sees MACD Histogram just turned negative

XFOR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 48 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XFOR as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

XFOR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XFOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for XFOR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XFOR's RSI Oscillator exited the oversold zone, 37 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 73 cases where XFOR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The 10-day moving average for XFOR crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +8.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where XFOR advanced for three days, in 177 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

XFOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. XFOR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.028) is normal, around the industry mean (3.596). P/E Ratio (2.224) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (22.676) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XFOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
DYN vs XFOR: Fundamental Ratings
DYN
XFOR
OUTLOOK RATING
1..100
3374
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6161
P/E GROWTH RATING
1..100
2165
SEASONALITY SCORE
1..100
n/a49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DYN's Valuation (42) in the Electric Utilities industry is in the same range as XFOR (73) in the Biotechnology industry. This means that DYN’s stock grew similarly to XFOR’s over the last 12 months.

DYN's Profit vs Risk Rating (96) in the Electric Utilities industry is in the same range as XFOR (100) in the Biotechnology industry. This means that DYN’s stock grew similarly to XFOR’s over the last 12 months.

DYN's SMR Rating (98) in the Electric Utilities industry is in the same range as XFOR (99) in the Biotechnology industry. This means that DYN’s stock grew similarly to XFOR’s over the last 12 months.

DYN's Price Growth Rating (61) in the Electric Utilities industry is in the same range as XFOR (61) in the Biotechnology industry. This means that DYN’s stock grew similarly to XFOR’s over the last 12 months.

DYN's P/E Growth Rating (21) in the Electric Utilities industry is somewhat better than the same rating for XFOR (65) in the Biotechnology industry. This means that DYN’s stock grew somewhat faster than XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYNXFOR
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 20, 2026
Stock price -- (DYN: $15.87 vs. XFOR: $2.98)
Brand notoriety: DYN and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 114% vs. XFOR: 60%
Market capitalization -- DYN: $3.37B vs. XFOR: $315.29M
DYN [@Biotechnology] is valued at $3.37B. XFOR’s [@Biotechnology] market capitalization is $315.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green while XFOR’s FA Score has 0 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • XFOR’s FA Score: 0 green, 5 red.
According to our system of comparison, DYN is a better buy in the long-term than XFOR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 5 TA indicator(s) are bullish while XFOR’s TA Score has 5 bullish TA indicator(s).

  • DYN’s TA Score: 5 bullish, 6 bearish.
  • XFOR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than DYN.

Price Growth

DYN (@Biotechnology) experienced а -11.78% price change this week, while XFOR (@Biotechnology) price change was -7.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.65%. For the same industry, the average monthly price growth was -12.38%, and the average quarterly price growth was -24.65%.

Reported Earning Dates

DYN is expected to report earnings on Mar 04, 2027.

XFOR is expected to report earnings on Mar 23, 2027.

Industries' Descriptions

@Biotechnology (-5.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+1.01%
RNA - DYN
64%
Loosely correlated
+5.12%
RCKT - DYN
55%
Loosely correlated
N/A
EDIT - DYN
54%
Loosely correlated
-3.39%
STOK - DYN
54%
Loosely correlated
+0.90%
CLDX - DYN
53%
Loosely correlated
+1.49%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with DYN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
-0.67%
DYN - XFOR
45%
Loosely correlated
+1.01%
BNTC - XFOR
41%
Loosely correlated
-1.57%
SLDB - XFOR
40%
Loosely correlated
+1.42%
EDIT - XFOR
38%
Loosely correlated
-3.39%
TSHA - XFOR
38%
Loosely correlated
-5.51%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IGIB50.740.02
+0.04%
iShares 5-10 Year Investment Grade Corporate Bond ETF (IGIB)
WIA7.50N/A
N/A
Western Asset Inflation-Linked Income Fund
SXQG31.56-0.49
-1.53%
ETC 6 Meridian Quality Growth ETF (SXQG)
FDMO82.72-1.80
-2.13%
Fidelity Momentum Factor ETF (FDMO)
UGE21.17-0.72
-3.29%
ProShares Ultra Consumer Staples (UGE)
Interesting Articles